DTS-108

• UNSPSC Description:

  DTS-108 is a prodrug of SN38 (HY-13704) (a Topoisomerase I inhibitor). DTS-108 is a conjugate generated by linking SN38 to a human oligopeptide via an esterase sensitive cross-linker. DTS-108 exhibits anti-tumor activity against colorectal, lung, and mammary cancer[1][2].

• Target Antigen:

  Peptide-Drug Conjugate (PDC); Topoisomerase

• Type:

  Peptides

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dts-108.html

• Smiles:

  C(C)C1=C2C(C=3N(C2)C(=O)C4=C(C3)[C@](CC)(O)C(=O)OC4)=NC=5C1=CC(OC(=O)[C@@H]6CC[C@@H](CNC(=O)[C@@H]7CC[C@@H](CN8C(=O)C(SC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC9=CN=CN9)C(N[C@H](C(N[C@H](C(=O)N%10[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC(O)=O)=O)CCSC)=O)CCCNC(=N)N)=O)[C@@H](C)O)=O)[C@H](C)C)=O)CCCNC(=N)N)=O)CCC%10)CCCNC(=N)N)=O)C(C)C)=O)=O)CCCNC(=N)N)=O)CC(C)C)=O)CCCCN)=O)CC(C)C)=O)=O)CCCNC(=N)N)=O)CCCCN)=O)C(C)C)=O)N)CC8=O)CC7)CC6)=CC5

• Molecular Weight:

  3170.80

• References & Citations:

  [1]Meyer-Losic, et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008, 14(7), 2145–2153.|[2]Coriat, et al. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. International journal of nanomedicine. 2016, 11, 6207–6216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  951792-83-9